For a number of years, researchers in the Royal Victoria Hospital in Belfast have been developing tests for Meningitis and Group B Streptococcus. HSC R&D Division has funded some of this work.
This research has resulted in a spin-out company, HiberGene Diagnostics Limited (“HiberGene”) based in Dublin, who have been developing these tests along with a range of other molecular diagnostics tests which will enable the rapid diagnosis of multiple infectious diseases.
The Company recently received a €2 million investment from Enterprise Ireland, Kernel Capital through the Bank of Ireland MedTech Accelerator Fund, and Private Investors. They aim to use this funding to support the commercialisation of its first two molecular tests for Meningococcal Meningitis and Group B Streptococcus (GBS).
For news about the meningitis diagnostic patent granted in usa
For an update on Belfast Trust licensing the rapid Group B Streptococcus diagnostic
Please see the HSC Innovation website for more details:
